Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma Clinical Trial

Official title:

A Phase III, Randomized, Three-arm, Double-blind, Placebo-controlled, International Multi-center Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Lenvatinib and Gemcitabine-based Chemotherapy Compared With Gemcitabine-based Chemotherapy as First-line Treatment in Patients With Unresectable Advanced Intrahepatic Cholangiocarcinoma (ICC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05342194
• Other study ID #: JS001-039-III-ICC
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: October 1, 2022
• Est. completion date: May 31, 2027

Study information

• Verified date: April 2022
• Source: Shanghai Junshi Bioscience Co., Ltd.
• Contact: Jiazheng Yan
• Phone: +86 158 2259 6147
• Email: jiazheng_yan[@]junshipharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, prospective, randomized, three-arm, double-blind, placebo-controlled, international multicenter study to evaluate the efficacy and safety of toripalimab in combination with lenvatinib and gemcitabine-based chemotherapy compared with gemcitabine-based chemotherapy as first-line treatment for unresectable advanced ICC.

This study will enroll approximately 480 patients with unresectable advanced ICC who have received no prior systemic therapy. Patients who meet the requirements will be randomly assigned to Treatment Arm A: Toripalimab, lenvatinib, and gemcitabine-based chemotherapy or Treatment Arm B: Toripalimab, oral placebo, and gemcitabine-based chemotherapy or Treatment Arm C: Intravenous placebo, oral placebo, and gemcitabine-based chemotherapy.

All patients will receive standard chemotherapy (GEMOX or GC per Investigator decision) for a maximum of 8 cycles. After the completion of standard chemotherapy, all patients continue to receive maintenance therapy with toripalimab injection or its placebo in combination with lenvatinib mesylate capsule or its placebo until unacceptable toxicity, confirmed disease progression and loss of clinical benefit as determined by the investigators, start of new anti-cancer therapy, death, other conditions requiring termination of study treatment, or the patient meets the criteria for study withdrawal, whichever occurs first.

In the absence of unacceptable toxicity, patients who meet criteria for unconfirmed disease progression per RECIST v1.1 while receiving toripalimab, lenvatinib, or their placebos will be permitted to continue treatment if their clinical status or symptoms are stable or improved (as determined by the investigators) or until loss of clinical benefit. Patients with confirmed disease progression should discontinue toripalimab, lenvatinib, or their placebos.

Tumor assessments will be performed at screening and during the study treatment per protocol. In the absence of progression, tumor assessments will continue as scheduled, regardless of whether study treatment ends, until confirmed disease progression or other criteria for study withdrawal are met, whichever occurs first. Patients who meet RECIST v1.1 criteria for progression should undergo tumor assessments as scheduled if clinical benefits of continuing study treatment are determined by investigators until progression is confirmed per iRECIST (iCPD), or the criteria for study withdrawal are met, whichever occurs first.

Computerized tomography (CT)/magnetic resonance imaging (MRI) scans for efficacy evaluation will be performed at baseline, every 6 weeks (Q6W) in the first year (52 weeks), and every 9 weeks (Q9W) in the second year (after week 52).

All AEs and concomitant medications during the study will be recorded. An end-of-treatment (EOT) visit will be performed within 30 days after the last dose of study treatment or termination of study treatment is confirmed by the investigator. After the EOT visit, follow-up for survival (telephone visit is allowed) will be conducted and AEs and subsequent anti-cancer therapy will be collected.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 480
• Est. completion date: May 31, 2027
• Est. primary completion date: May 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Age of 18-75 years (inclusive), male or female;

2. Volunteer to participate in the study by signing the informed consent form and the ability to comply with the study protocol;

3. Advanced ICC with diagnosis confirmed by histology or cytology;

4. Stage II, III, or IV per TNM staging for ICC of the American Joint Committee on Cancer (AJCC) (8th edition, 2017). Those with Stage II or III should be determined to be unresectable by the investigator;

5. Patients with no prior systemic chemotherapy or targeted therapy or loco-regional therapy (including but not limited to transarterial chemoembolization, transarterial embolization, transarterial chemotherapy or transarterial radioembolization) for ICC. Patients with recurrent disease more than 6 months after completion of adjuvant chemotherapy following curative resection are eligible;

6. Measurable lesion per RECIST v1.1;

7. Child-Pugh class A with no history of hepatic encephalopathy;

8. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1;

9. Life expectancy =12 weeks;

Exclusion Criteria:

1. Diagnosis of hepatocellular carcinoma (HCC), mixed cholangiocarcinoma and HCC, sarcomatoid hepatocellular carcinoma, or hepatic fibrolamellar carcinoma by histology or cytology;

2. History of malignancy other than ICC within 5 years prior to screening, with the exception of localized malignancies that have been cured, including non-melanoma skin cancers, cervical carcinoma in situ, breast carcinoma in situ, and papillary thyroid carcinoma;

3. Prior radiotherapy for ICC within 4 weeks prior to randomization;

4. Major surgical procedures within 4 weeks prior to randomization;

5. Side effects from prior therapy (except alopecia and pigmentation) that has not recovered to = grade 1 (per NCI-CTCAE v5.0) or levels specified in the inclusion/exclusion criteria;

6. Uncontrolled pericardial effusion, pleural effusion, or clinically significant moderate or severe ascites that is symptomatic or requires thoracentesis or paracentesis during the screening phase for control of symptoms;

7. Gastrointestinal (GI) hemorrhage within 6 months prior to randomization and/or gastrointestinal varices that have not been assessed and treated, if appropriate, within 6 months prior to randomization.

8. Gastrointestinal or non-gastrointestinal fistula, gastrointestinal perforation, or abdominal abscess within 6 months prior to randomization;

9. Ongoing or a history of recurrent intestinal obstruction. Patients with a single episode of intestinal obstruction that has fully resolved following treatment are eligible allowed;

10. History of serious cardiovascular and cerebrovascular diseases:

11. Significant bleeding and coagulopathy or other evidence of bleeding diathesis, to include:

12. Pre-existing CNS metastases and/or meningeal metastases (including dural metastases and leptomeningeal metastases);

13. Serious non-healing wound, active ulcer, or untreated bone fracture;

14. Vaccination with live virus or bacteria within 30 days prior to randomization;

15. Active autoimmune disease or history of autoimmune disease

Related Conditions & MeSH terms

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Intervention

Drug:
• Toripalimab
240 mg IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
• Lenvatinib mesylate capsules
8 mg orally (po) once daily (QD)
• Placebo IV
Placebo IV on day 1 of each 21-day treatment cycle (Q3W) for up to 35 treatment cycles
• Oral placebo
Oral placebo po QD continuously
• Oxaliplatin for injection
85 mg/m2 IV, on day 1 of each 21-day treatment cycle (Q3W) up to 8 cycles
• Gemcitabine hydrochloride
1 g/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles
• Cisplatin
25 mg/m2 IV, on day 1 and day8 of each 21-day treatment cycle (Q3W) up to 8 cycles

Locations

Country	Name	City	State
China	Zhongshan Hospital affiliated to Fudan University	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Junshi Bioscience Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	OS rates	1-year and 2-year OS rates between Arm A and Arm C	Until 2 years after the last subject was enrolled
Other	OS rates	1-year and 2-year OS rates between Arm B and Arm C	Until 2 years after the last subject was enrolled
Other	adverse events (AE), immune-related adverse events (irAE) and serious adverse events (SAE)	To evaluate incidence, severity and outcome of adverse events (AE), immune-related adverse events (irAE) and serious adverse events (SAE)	Until 2 years after the last subject was enrolled
Primary	Overall survival (OS) in Arm A compared with Arm C (OS A vs. C)	OS is defined as the time from randomization to death due to any cause. Overall survival will be compared between Arm A and Arm C	Until 2 years after the last subject was enrolled
Secondary	OS in Arm B compared with Arm C (OS B vs. C)	OS is defined as the time from randomization to death due to any cause. Overall survival will be compared between Arm B and Arm C	Until 2 years after the last subject was enrolled
Secondary	Investigator-determined progression-free survival (PFS)	Investigator-determined progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (v1.1) in Arm A compared with Arm C (PFS A vs. C);	Until 2 years after the last subject was enrolled
Secondary	Investigator-determined progression-free survival (PFS)	Investigator-determined PFS according to RECIST v1.1 in Arm B compared with Arm C (PFS B vs. C);	Until 2 years after the last subject was enrolled
Secondary	Investigator-determined objective response rate (ORR)	Investigator-determined objective response rate (ORR) according to RECIST v1.1 in Arm A compared with Arm C (ORR A vs. C)	Until 2 years after the last subject was enrolled
Secondary	Investigator-determined objective response rate (ORR)	Investigator-determined ORR according to RECIST v1.1 in Arm B compared with Arm C (ORR B vs. C)	Until 2 years after the last subject was enrolled